Grants for Public housing authorities - Federal

This funding opportunity provides financial support to various organizations working to strengthen public health systems in Kenya, focusing on preventing and responding to health threats and improving overall health security.

This funding opportunity provides additional financial support for early-stage cancer researchers who have made significant progress in their work, allowing them to extend their research efforts and move towards greater independence in their scientific careers.

This funding opportunity supports educational and mentorship programs that encourage undergraduate and post-baccalaureate students from diverse backgrounds to pursue careers in genomics research.

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applications proposing studies that include but not limited to model animal research or observational studies involving humans should submit under the companion Clinical Trials Not Allowed version of this FOA.

This funding opportunity supports researchers investigating new and existing risk factors for liver cancer, focusing on population-based studies to improve understanding and prevention of the disease in the U.S.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.

This funding opportunity provides financial support to public housing authorities, nonprofits, and other eligible organizations to hire service coordinators who help residents of public and Indian housing communities access resources for economic and housing self-sufficiency.

The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research. To accomplish the stated over-arching goal, this NOFO will support creative educational activities with a primary focus on: Courses for Skills Development Specifically, this UE5 program will support faculty members at minority-serving institutions (MSIs) to create undergraduate or masters degree courses in computational genomics, data science, or a combination of these topics. Support for this activity will be provided by the Educational Hub for Enhancing Diversity in Computational Genomics and Data Science, created through RFA-HG-22-002. For developing skills in computational genomics and data science, these courses will leverage the resources of NIH cloud computing platforms such as NHGRIs AnVIL and the All of Us Researcher Workbench.

This grant provides funding for researchers and institutions to develop advanced imaging and biomarker technologies that improve the early detection of aggressive cancers and precancerous lesions, ultimately enhancing patient outcomes and clinical decision-making.

This funding opportunity supports innovative community-based projects aimed at reducing health disparities related to dementia and cognitive decline among underserved populations as they age.

This grant provides funding and support for underrepresented clinical scientists to develop their research skills in cancer-related fields, with a focus on addressing health disparities and preparing them for future research funding opportunities.

This funding opportunity provides financial support for early-career researchers from underrepresented backgrounds to lead independent clinical trials and develop their research skills under the mentorship of experienced scientists.

The Bureau of Land Management’s (BLM) Alaska Aquatic Resources Program protects and restores riparian and wetland areas, aquatic habitats, and water resources to provide functioning ecosystems for a combination of balanced and diverse uses including fish and wildlife, and for the long-term needs of future generations. Policy guidance for the Program ensures that public land management based on multiple use and sustained yield provides healthy and productive riparian, wetland, and aquatic habitat, achieves land health standards, and considers society’s long-term needs for healthy watersheds. The issues the Program addresses are diverse and include restoration, habitat fragmentation and degradation, drought resiliency, water availability, and aquatic invasive species. Program staff provide professional expertise and policy guidance to BLM managers, Federal, State, Tribal, and local governments, and non-governmental partners on these issues, and implement the best management practices to minimize or avoid impacts to water resources, riparian and wetland areas, and aquatic habitats on public lands. This program supports projects funded through the Infrastructure Investment and Jobs Act, Section 40804 (b) Ecosystem Restoration. This program also supports projects funded through the Inflation Reduction Act (IRA), Sections 50221 Resilience, 50222 Ecosystems Restoration and 50303 DOI.

This funding opportunity provides $25 million to strengthen Nigeria's health systems and workforce, enabling better detection and response to public health threats at national and local levels.

This grant provides funding for researchers to study how the combined stigma of HIV and cancer affects health outcomes in HIV-positive individuals diagnosed with cancer, with a focus on developing interventions to reduce this stigma.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and test the navigator models ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the personalized match to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R34

This funding opportunity supports research projects that develop innovative strategies to improve HIV prevention and treatment outcomes, particularly for marginalized populations, by addressing barriers and enhancing community engagement.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

This funding opportunity is designed to support the establishment of research centers that provide essential resources and infrastructure for advancing studies on rheumatic diseases, encouraging collaboration among researchers and institutions.

This funding opportunity provides financial support for research and evaluation projects aimed at improving policing practices, enhancing community relations, and ensuring evidence-based policymaking, targeting a wide range of eligible applicants including government entities, educational institutions, and nonprofit organizations.